Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRMD KORU Medical Systems	$2.06 -2.8%	$2.19	$1.98 ▼ $4.48	$94.16M	0.53	96,382 shs	61,319 shs
PYPD PolyPid	$4.30 -3.2%	$5.24	$3.57 ▼ $13.50	$20.64M	1.41	6,708 shs	5,248 shs
SOLY Soliton	$22.58	$21.55	$7.40 ▼ $22.60	$487.66M	0.19	347,827 shs	N/A
TELA TELA Bio	$5.15 -0.4%	$5.98	$4.23 ▼ $11.26	$126.95M	0.95	135,540 shs	95,186 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRMD KORU Medical Systems	-1.40%	-0.93%	+1.92%	+2.42%	-47.00%
PYPD PolyPid	-6.33%	-4.52%	-15.91%	-32.01%	-67.10%
SOLY Soliton	0.00%	0.00%	0.00%	0.00%	0.00%
TELA TELA Bio	+4.02%	+5.08%	-2.45%	-25.61%	-51.36%

Bitcoin Rockets To Record High But Buy THIS Instead (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KRMD KORU Medical Systems	1.9782 of 5 stars	3.5	1.0	0.0	0.0	2.9	2.5	0.6
PYPD PolyPid	1.2824 of 5 stars	0.0	5.0	0.0	0.0	3.3	1.7	0.6
SOLY Soliton	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	1.6576 of 5 stars	3.5	2.0	0.0	0.0	1.8	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRMD KORU Medical Systems	3.00	Buy	$3.50	69.90% Upside
PYPD PolyPid	3.00	Buy	N/A	N/A
SOLY Soliton	N/A	N/A	N/A	N/A
TELA TELA Bio	3.00	Buy	$13.67	165.37% Upside

Current Analyst Ratings

Latest TELA, SOLY, KRMD, and PYPD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/22/2024	TELA TELA Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
3/22/2024	TELA TELA Bio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $12.00
3/14/2024	KRMD KORU Medical Systems	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRMD KORU Medical Systems	$28.52M	3.30	N/A	N/A	$0.45 per share	4.58
PYPD PolyPid	N/A	N/A	N/A	N/A	($1.27) per share	N/A
SOLY Soliton	N/A	N/A	N/A	N/A	$1.46 per share	N/A
TELA TELA Bio	$58.45M	2.17	N/A	N/A	$0.77 per share	6.69

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRMD KORU Medical Systems	-$13.74M	-$0.29	N/A	N/A	N/A	-48.18%	-27.82%	-21.30%	5/1/2024 (Confirmed)
PYPD PolyPid	-$23.86M	-$19.68	N/A	N/A	N/A	N/A	-450.37%	-101.27%	5/8/2024 (Estimated)
SOLY Soliton	-$14.54M	-$1.01	N/A	N/A	N/A	N/A	-71.85%	-62.92%	N/A
TELA TELA Bio	-$46.66M	-$2.07	N/A	N/A	N/A	-79.83%	-201.62%	-58.60%	5/9/2024 (Estimated)

Latest TELA, SOLY, KRMD, and PYPD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2024	N/A	KRMD KORU Medical Systems	-$0.04	N/A	+$0.04	N/A	N/A	N/A
3/21/2024	Q4 2023	TELA TELA Bio	-$0.44	-$0.53	-$0.09	-$0.53	$16.65 million	$17.00 million
3/13/2024	Q4 2023	KRMD KORU Medical Systems	-$0.04	-$0.02	+$0.02	$0.12	$7.01 million	$7.19 million
2/14/2024	Q4 2023	PYPD PolyPid	-$2.17	-$3.97	-$1.80	-$3.97	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRMD KORU Medical Systems	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A
SOLY Soliton	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRMD KORU Medical Systems	0.02	4.55	3.77
PYPD PolyPid	2.17	0.83	0.83
SOLY Soliton	N/A	5.47	5.37
TELA TELA Bio	2.15	4.23	3.45

Ownership

Institutional Ownership

Company	Institutional Ownership
KRMD KORU Medical Systems	58.60%
PYPD PolyPid	26.47%
SOLY Soliton	35.11%
TELA TELA Bio	94.35%

Insider Ownership

Company	Insider Ownership
KRMD KORU Medical Systems	25.60%
PYPD PolyPid	24.70%
SOLY Soliton	12.00%
TELA TELA Bio	5.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
KRMD KORU Medical Systems	82	45.71 million	34.01 million	Optionable
PYPD PolyPid	59	4.80 million	3.61 million	Optionable
SOLY Soliton	14	21.60 million	19.01 million	Not Optionable
TELA TELA Bio	227	24.65 million	23.25 million	Optionable

TELA, SOLY, KRMD, and PYPD Headlines

Source	Headline
	TELA Bio Launches Innovative Hernia Repair Device in the U.S. Market msn.com - April 17 at 9:16 AM
	TELA Bio launches OviTex IHR for inguinal hernia repair in US msn.com - April 16 at 5:32 PM
	TELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repair pharmabiz.com - April 16 at 7:29 AM
	TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures globenewswire.com - April 15 at 7:00 AM
	MDXG: Legal Avenues finance.yahoo.com - April 11 at 1:10 PM
	TELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical Affairs msn.com - April 10 at 6:58 AM
	TELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy finanznachrichten.de - April 8 at 4:17 PM
	TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy globenewswire.com - April 8 at 7:00 AM
	TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024 msn.com - March 25 at 8:23 AM
	Analysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Results finance.yahoo.com - March 24 at 5:22 PM
	TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript seekingalpha.com - March 23 at 11:14 PM
	TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022) finance.yahoo.com - March 23 at 8:39 AM
	TELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery stockhouse.com - March 22 at 5:36 PM
	TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 22 at 5:36 PM
	JMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA) marketbeat.com - March 22 at 2:10 PM
	Piper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00 marketbeat.com - March 22 at 10:25 AM
	Q4 2023 TELA Bio Inc Earnings Call finance.yahoo.com - March 22 at 7:36 AM
	Recap: TELA Bio Q4 Earnings benzinga.com - March 21 at 9:14 PM
	TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023 msn.com - March 21 at 9:14 PM
	TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023 finance.yahoo.com - March 21 at 9:14 PM
	TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates zacks.com - March 21 at 6:31 PM
	Strategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA Bio markets.businessinsider.com - March 21 at 4:13 PM
	TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results finance.yahoo.com - March 21 at 4:13 PM
	TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results globenewswire.com - March 21 at 4:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

KORU Medical Systems

NASDAQ:KRMD

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

PolyPid

NASDAQ:PYPD

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Soliton

NASDAQ:SOLY

Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.

TELA Bio

NASDAQ:TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial